NCI-MATCH / EAY131 Findings and Publications

Treatment arm findings and publications on special topics about the NCI-MATCH precision medicine trial appear on a rolling basis. This section of the website contains a comprehensive list of all publications associated with the trial. See the table below. Hover over any of the column headings and click the up/down arrows to sort. You can also search by keyword.

We update this table on an ongoing basis as new publications appear.

TopicTitle and Citation
Arm K1 Final Results

Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1

Gong J. JCO Precis Oncol. April 2024

Arm K2 Final Results

Phase II Study of Erdafitinib in Patients With Tumors With Fibroblast Growth Factor Receptor Mutations or Fusions: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K2

Citation: Gong J. JCO Precis Oncol. April 2024

Arm J Final Results

Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI–MATCH ECOG–ACRIN Trial (EAY131) Subprotocol J
Citation: Connolly RM. Clin Cancer Res. March 2024

Arm E Final Results

Phase II Study of Osimertinib in Patients With Epidermal Growth Factor Receptor Mutations: Results From the NCI-MATCH ECOG-ACRIN (EAY131) Trial Subprotocol E

Chen MF. JCO Precis Oncol. February 2024

ImplementationThe NCI-MATCH trial: lessons for precision oncology
O'Dwyer PJ. Nature Medicine. June 2023
Arm Z1B Final ResultsPhase II Study of Palbociclib (PD-0332991) in CCND1, 2, or 3 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1B
Clark AS. Clin Cancer Res. April 2023
Arms S1 & S2 Final ResultsTrametinib in Patients With NF1-, GNAQ-, or GNA11-Mutant Tumors: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols S1 and S2
Wisinski KB. JCO Precis Oncol. April 2023
Arm B Final Results

Phase II Study of Afatinib in Patients With Tumors With Human Epidermal Growth Factor Receptor 2–Activating Mutations: Results From the National Cancer Institute–Molecular Analysis for Therapy Choice ECOG-ACRIN Trial (EAY131) Subprotocol EAY131-B
Bedard PL. JCO Precis Oncol. August 2022

Arms F & G Final Results

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
Mansfield AS, NPJ Precis Oncol. March 2022

Arm I Final Results

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I
Krop IE. JCO Precis Oncol. February 2022

Arm Z1F Final Results

Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F
Damodaran S, J Clin Oncol. February 2022

Arm Z1A Final ResultsDifferential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors
Cleary JM. Clin Cancer Res. June 2021
Arm Y Final ResultsEffect of Capivasertib in Patients with an AKT1 E17K-mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial
Kalinsky KM. JAMA Oncol. December 2020
Central Screening CohortMolecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)
Flaherty KT, J Clin Oncol. October 2020
Physician SurveyTumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial
Chen AP, JCO Precis Oncol. October 2020
Arm H Final ResultsDabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H
Salama AKS. J Clin Oncol. August 2020
Arm W Final ResultsPhase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W
Chae YK. J Clin Oncol. May 2020
Arm R Final ResultsTrametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: Results from NCI-MATCH (EAY131)
Johnson DB. Clin Cancer Res. April 2020
ImplementationThe Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design
Flaherty KT. J Natl Cancer Inst. January 2020
Arm Z1D Final ResultsNivolumab Is Effective in Mismatch Repair–Deficient Noncolorectal Cancers: Results From Arm Z1D—A Subprotocol of the NCI-MATCH (EAY131) Study
Azad NS. J Clin Oncol. January 2020
Arm Q Final ResultsAdo-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Subprotocol Q
Jhaveri KL. Ann Oncol. November 2019
Immunohistochemical AssaysValidation of Immunohistochemical Assays for Integral Biomarkers in the NCI-MATCH EAY131 Clinical Trial
Koury JD. Clin Cancer Res. January 2018
Next-Gen Sequencing AssayConsiderations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience
Lih CJ. Curr Probl Cancer. May-June 2017
Defining PrecisionDefining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH
O'Sullivan Coyne G. Curr Probl Cancer. May-June 2017
Next-Gen Sequencing AssayAnalytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial
Molecular Analysis for Therapy Choice Clinical Trial
Lih CJ. J Mol Diagn. March 2017
OverviewAn overview of the NCI Precision Medicine trials-NCI MATCH and MPACT
Do K. Chin Clin Oncol. September 2015
OverviewMolecular Analysis for Therapy Choice: NCI MATCH
Conley BA. Semin Oncol. June 2014
 
ECOG-ACRIN Cancer Research Group